title: Prospective trial to identify optimal bladder cancer surveillance protocol: reducing costs while maximizing sensitivity.
abstract: OBJECTIVE
  • To assess the cost-effectiveness of using cytological evaluation, NMP22 BladderChek®, and fluorescence in situ hybridization (FISH) UroVysion® in addition to cystoscopy in patients with a history of bladder cancer undergoing surveillance for recurrence.
  
  
  METHODS
  • In all, 200 consecutive patients with a history of bladder cancer not invading the muscle were prospectively enrolled at The University of Texas MD Anderson Cancer Center. • Five surveillance strategies were compared: (i) cystoscopy alone; (ii) cystoscopy and NMP22; (iii) cystoscopy and FISH; (iv) cystoscopy and cytology; and (v) cystoscopy and positive NMP22 confirmed by positive FISH. • The cost per cancer detected was calculated. • For patients with an initial positive test and negative cystoscopy, tumour detected at first follow-up was assumed to be too small to be visualized at the initial assessment and the biomarker was credited with early detection.
  
  
  RESULTS
  • Cancer was detected in 13 patients at study entry. • Detection rates for the five surveillance strategies were: (i) 52%, (ii) 56%, (iii) 72%, (iv) 60%, and (v) 56%. • The costs per tumour detected (at the time of initial marker analysis) were (i) $7692; (ii) $12,000; (iii) $26,462; (iv) $11,846; and (v) $10,292. • When early detection of biomarkers was factored in, the CPTD became: (i) $7692; (ii) $11,143; (iii) $19,111; (iv) $10,267; and (v) $9557. • There were 12 new cancers detected at first follow-up (median time, 4.1 months). None of the tumours detected by biomarkers but not by cystoscopy were invasive.
  
  
  CONCLUSIONS
  • Cystoscopy alone remains the most cost-effective strategy to detect recurrence of bladder cancer not invading the muscle. • The addition of urinary markers adds to cost, without improved detection of invasive disease.
authors.affiliation: Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. akamat@mdanderson.org
authors.forename: Ashish M
authors.initials: AM
authors.lastname: Kamat
authors.forename: Jose A
authors.initials: JA
authors.lastname: Karam
authors.forename: H Barton
authors.initials: HB
authors.lastname: Grossman
authors.forename: A Karim
authors.initials: AK
authors.lastname: Kader
authors.forename: Mark
authors.initials: M
authors.lastname: Munsell
authors.forename: Colin P
authors.initials: CP
authors.lastname: Dinney
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002985:Clinical Protocols; D003362:Cost-Benefit Analysis; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000175:diagnosis* / Q000191:economics*; D011159:Population Surveillance; D011446:Prospective Studies; D001749:Urinary Bladder Neoplasms / Q000175:diagnosis* / Q000191:economics*; D055815:Young Adult